Metabolomic Signatures in Pediatric Crohn’s Disease Patients with Mild or Quiescent Disease Treated with Partial Enteral Nutrition: A Feasibility Study

• Published in: SLAS technology Vol. 26; no. 2; pp. 165 - 177
• Main Authors: Marques, Jair Gonzalez, Shokry, Engy, Frivolt, Klara, Werkstetter, Katharina Julia, Brückner, Annecarin, Schwerd, Tobias, Koletzko, Sibylle, Koletzko, Berthold
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA Elsevier Inc 01.04.2021; SAGE Publications
• Subjects: enteral nutrition; inflammatory markers; pediatric inflammatory bowel disease; untargeted metabolomics; xenobiotics; enteral nutrition; inflammatory markers; pediatric inflammatory bowel disease; untargeted metabolomics; xenobiotics
• ISSN: 2472-6303; 2472-6311
• DOI: 10.1177/2472630320969147

Little is known about the metabolic response of pediatric Crohn’s disease (CD) patients to partial enteral nutrition (PEN) therapy and the impact of disease activity and inflammation. We analyzed plasma samples from a nonrandomized controlled intervention study investigating the effect of partial enteral nutrition (PEN) on bone health and growth throughout one year with untargeted metabolomics using high-performance liquid chromatography (HPLC) coupled with high-resolution mass spectrometry (HRMS). Thirty-four paired samples from two time points (baseline and 12 months) were analyzed. Patients (median age: 13.9 years, range: 7–18.9 years, 44% females) were in remission or had mild disease activity. The intervention group received a casein-based formula for 12 months, providing ~25% of estimated daily energy requirements. Sparse partial least squares discriminant analysis (splsda) was applied for group discrimination and identifying sources of variation to identify the impact of PEN. We also investigated the correlation of metabolites with inflammation markers, including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fecal calprotectin. After 12 months, our results show substantial difference between PEN and non-PEN groups in the metabolome of CD patients in remission or with mild disease activity. Inflammatory markers were associated with individual compounds and chemical classes such as isoprenoids and phospholipids. Identified compounds comprise metabolites produced by human or bacterial metabolism, as well as xenobiotics recognized as flavoring agents and environmental contaminants and their biotransformation products. Further longitudinal studies that also include patients with higher disease activity are warranted to evaluate the suitability of these metabolic biomarkers for predicting disease activity.